Skip to main content
. 2012 Jan 17;61(2):474–484. doi: 10.2337/db11-0141

FIG. 6.

FIG. 6.

Enhanced Bmf expression in RPTs from human kidneys from patients with diabetes. A: Bmf immunohistochemical staining in human kidney sections (original magnification ×200) from three nondiabetic cancer patients (a, patient with papillary variant carcinoma; b, patient with clear cell carcinoma; and c, patient with thyroid-like renal carcinoma) and three diabetic cancer patients (d, patient with papillary variant carcinoma and evidence of DN [nodular with tubular atrophy and interstitial fibrosis]; e, patient with clear cell carcinoma and no evidence of DN; and f, patient with clear cell carcinoma and nephroangiosclerosis with evidence of DN [secondary focal glomerulosclerosis, tubular atrophy, and interstitial fibrosis]). DT, distal tubule; G, glomerulus. B: Colocalization of Bmf expression and TUNEL-positive cells in human kidneys. Nondiabetic human kidney (patient I.D. #C,) and diabetic human kidney with DN (patient I.D. #D) were sectioned, subjected to TUNEL assay to visualize apoptotic cells (green), and then incubated with anti-Bmf antibody, followed by anti-goat AlexaFluor 594 to demonstrate Bmf expression (red). Cells staining positively for TUNEL and Bmf appear yellow (merged image). Original magnification ×200. Arrows indicate cells that stained positively for TUNEL and Bmf. G, glomerulus; DT, distal tubule. (A high-quality color representation of this figure is available in the online issue.)